Autologous Cell Therapy Market Research Report – Segmentation By Source (Bone Marrow, Epidermis, and Others); By Application (Neurology, Orthopedic, Cancer, Wound Healing (including Skin), Cardiovascular Disorders, Autoimmune Disorders, and Others); By End-User (Hospitals, Ambulatory Centers, and Research Centers) ;and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)

Global Autologous Cell Therapy Market size (2024-2030)

The Global Autologous Cell Therapy Market was valued at USD 10.56 billion and is projected to reach a market size of USD 32.27 billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 9%. . The Increasing Prevalence of Cardiovascular Diseases and the Growing Prevalence of Autoimmune Disorders are the major factor that is driving the growth of the industry.

Autologous Cell Therapy Market

Industry Overview:

In the area of medicine, autologous cell therapy (ACT) is a progressive technique. This is a present-day approach that uses the patient’s very own cells to deal with the patient’s condition. Autologous cell therapy, regularly recognized as mobile therapy, is a kind of cure in which cell components are brought into the patient’s (body) in order to enhance therapeutic effects whilst concurrently minimizing bad effects. T cells, stem cells, fibroblasts, dendritic cells, chondrocytes, and a range of different cells are utilized in mobile therapy cure processes, including cell therapy.

In this procedure, cells from a donor are produced and cultured outdoors of the physique earlier than being reintroduced into the recipient. This remedy lowers the risk related to the immune machine and bio-incompatibility, and it has been employed in the formation of pores and skin replacement by means of using bioengineering methods in some cases. Additionally, this remedy is positive in the cure of burns, the improvement of postoperative healing, and the cure of stress ulcers. Additionally, sickness transmission related to cells or grafts that are now not derived from the person offers extra advantages. When in contrast to contemporary transplant technologies, such as xenotransplants and allogeneic transplants, the remedy is regarded to be a safer and greater robust therapy option.

The principal elements attributing to the increase of the autologous cell therapy market are the rising incidence of persistent ailments such as autoimmune diseases, cancer, blood disorder, and others. A rise in the population struggling from continual illnesses is additionally propelling the demand for market growth.

COVID-19 impact on the Autologous Cell Therapy Market 

COVID-19 is an infectious sickness that originated in the Hubei province of Wuhan town in China in late December. The highly contagious disease, prompted by a virus, extreme acute respiratory syndrome coronavirus two (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the ailment has unfolded to nearly 213 international locations around the globe with the World Health Organization declaring it a public fitness emergency on March 11, 2020.

In the context of COVID-19, government agencies in various countries, lookup institutes, and many biotech and pharmaceutical companies are focusing on tremendous and fast technologies for the fast prognosis of COVID-19. Additionally, the growing medical trials for the usage of therapy for COVID-19 and the use of autologous cell therapies are predicted to make contributions to the boom of the market. For instance, as per medical in 2022, A medical study was started from January 2020 to March 2021 to learn about the population of all Swedish Citizens handled with autologous hematopoietic stem mobile phone transplantation for COVID-19 fantastic patients. The positive effects of such research can lead to the improvement of new cures for COVID-19 and for this reason, can propel the increase of the market.


The Increasing Prevalence of Cardiovascular Diseases and the Growing Prevalence of Autoimmune Disorders are driving the growth of the market

The increasing occurrence of cardiovascular diseases is growing the boom of the autologous cell therapy market. Some of the major elements of cardiovascular disease consist of an unhealthy diet, utilization of tobacco, and bodily inactivity among others which raise blood pressure and blood glucose inflicting obese and obesity. The growing occurrence of autoimmune disorders is growing the boom of the autologous cell therapy market. Autoimmune disorder assaults healthy cells, organs, and tissues. It can affect any phase of the physique that weakens the physique feature and can flip out to be existence threatening


The Inadequate Funding and High Cost Involved are restraining the growth of the market

Some of the factors that are set to impede the growth of the autologous cell therapy market are inadequate funding and the high cost involved in the treatment of the disease is restraining the growth of the market. The government has also imposed some bans on research and development which is also restraining the growth of the market.




Market Size Available

2023 - 2030

Base Year


Forecast Period

2024 - 2030


17.3 %

Segments Covered

By Source, Application, End User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regional Scope

North America, Europe, APAC, Latin America, Middle East & Africa

Key Companies Profiled

Pharmicell Co. Inc., Vericel Corporation, Castle Creek Biosciences Inc., Lineage Cell Therapeutics Inc., BrainStorm Cell Therapeutics, Regeneus Ltd., Caladrius Biosciences Inc, Opexa Therapeutics Inc, U.S. Stem Cell Inc, Takeda Pharmaceutical Company Limited.

This research report on the global Autologous Cell Therapy Market has been segmented and sub-segmented based on the Source, Application, End-User, and region.

Autologous Cell Therapy Market - By Source:

  • Bone Marrow
  • Epidermis
  • Others

By Source, The Bone Marrow section is estimated to witness the best possible CAGR for the forecast period. Bone marrow transplant refers to an approach for changing broken and destroyed cells with new stem cells in the bone marrow. Bone marrow is oftentimes used for autologous cell therapy as it can advantage humans with exceptional kinds of cancers (malignant) and non-cancer (benign) ailments and will pressure the market over the forecast period.

Autologous Cell Therapy Market - By Application:

  • Neurology
  • Cancer
  • Orthopedic
  • Wound Healing
  • Cardiovascular
  • Immune
  • Others

Based on the Application, The Neurology phase is estimated to witness the best possible CAGR for the forecast period. The cancer section is additionally predicted to develop at an extraordinary rate during the forecast period. The rise in the incidence of neurological disorders, cancer, and autoimmune issues helps to pressure the increase of this market for the duration of the forecasted period.

Autologous Cell Therapy Market - By End-User:

  • Hospitals
  • Research centers
  • Ambulatory centers

On the basis of end users, the research-use category led the Autologous Cell Therapy Market in 2023 and was once predicted to generate the most revenue. The majority of stem cells are being employed in research initiatives, which has resulted in a large income share for the research-use component of the industry. From 2023 to 2028, the location is expected to hold its role as the dominant region. It is predicted that cell-based redress will have enormous promise for replacing, repairing, restoring, or regenerating broken tissues, cells, and organs in the close to future. To produce such high-quality and protected treatments as a choice to standard treatment procedures, researchers are pouring millions of dollars into the lookup and improvement process.

Autologous Cell Therapy Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East
  • Africa

Geographically, North America is predicted to have the best market share in 2023, in accordance with estimates. Because of the large wide variety of facilities and establishments that are active in research and improvement in the discipline of stem cell treatment, the place accounts for a significant element of the global market. Out of the eight such main universities for the duration of the world, five are primarily based in the United States, together with the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University, the Harvard Stem Cell Institute at Harvard University, the Yale Stem Cell Center, and the Institute for Stem Cell Biology and Regenerative Medicine at Yale University.

The market for autologous cell therapy in the Asia Pacific is predicted to rise at a fast pace, ensuing in great income generation. It is projected that the growing investment by builders and shoppers in educating themselves about present-day medical therapies would extend the profits created via the rising economies of this region. Several stem mobile consortiums exist in Asian nations, with the purpose of assuring coordinated and centered research and improvement initiatives. Aside from that, sufferers from western countries have been noticed migrating to Asian nations for treatment, possibly because of the countries’ greater bendy legislative structures.

Autologous Cell Therapy Market Share by Company

  1. Pharmicell Co. Inc.
  2. Vericel Corporation
  3. Castle Creek Biosciences Inc.
  4. Lineage Cell Therapeutics Inc.
  5. BrainStorm Cell Therapeutics
  6. Regeneus Ltd.
  7. Caladrius Biosciences Inc
  8. Opexa Therapeutics Inc
  9. U.S. Stem Cell Inc
  10. Takeda Pharmaceutical Company Limited.

and others playing a pivotal role in the market. Mergers and acquisitions in the enterprise have enabled players to diversify and decorate their carrier services.

Recently, American Gene Technologies (AGT) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT103-T in the treatment of HIV patients.


  • Product Launch - In April 2022, Aspen Neuroscience, Inc., launched the first patient screening study of its kind, working with multiple clinical screening sites in the United States.

Chapter 1. AUTOLOGOUS CELL THERAPY MARKET – Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. AUTOLOGOUS CELL THERAPY MARKET – Executive Summary

2.1. Market Size & Forecast – (2024 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

      2.3.1. Impact during 2024 - 2030

      2.3.2. Impact on Supply – Demand

Chapter 3. AUTOLOGOUS CELL THERAPY MARKET – Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis


4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes


5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities


6.1. Bone Marrow

6.2. Epidermis

6.3. Others


7.1. Neurology

7.2. Cancer

7.3. Orthopedic

7.4. Wound Healing

7.5. Cardiovascular

7.6. Immune

7.7. Others


8.1. Hospitals

8.2. Research centres

8.3. Ambulatory centres


9.1. North America

9.2. Europe

9.3. The Asia Pacific

9.4.Latin  America

9.5. Middle-East and Africa

Chapter 10. AUTOLOGOUS CELL THERAPY MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Developments)

10.1. Pharmicell Co. Inc.,

10.2. Vericel Corporation

10.3. Castle Creek Biosciences Inc.,

10.4. Lineage Cell Therapeutics Inc.,

10.5. BrainStorm Cell Therapeutics

10.6. Regeneus Ltd.,

10.7. Caladrius Biosciences Inc

10.8. Opexa Therapeutics Inc,

10.9. U.S. Stem Cell Inc,

10.10. Takeda Pharmaceutical Company Limited



Download Sample

The field with (*) is required.

Choose License Type









Analyst Support

Every order comes with Analyst Support.


We offer customization to cater your needs to fullest.

Verified Analysis

We value integrity, quality and authenticity the most.